And what you see here on the left hand side is the kidney and the bars should go down. Lower bars are better, because it shows how much of your drug is in the kidney. Lower is better. You see the solid €" the red solid, that's a parental DARPin. Then you have the striped red that is a different approach on top of cells, that's now blue and it again reduces by 60%. So, we are working on a suite of ways to reduce kidney €" and they are additive. At the same time, if you look at the tumor side, you see the tumor accumulation stays the same. So we have no impact on that. So what we are doing is we are moving the tumor to kidney ratio into a favorable direction. And now switching a bit gear going from science to corporate sustainability and corporate sustainability is maybe a large abstract for it.